Autism Spectrum Disorders Treatment Study (Autism Speaks Clinical Trials Network)
This study is evaluating the effects of the medication memantine (Namenda) on improving motor skills, memory and learning in children with autism spectrum disorders (ASDs), ages 6 to 12 years old. Patients will receive comprehensive clinical, diagnostic and neuropsychological evaluations as part of the study assessment procedures. Following the evaluation, patients will be randomly assigned to treatment or placebo (sugar pill) and closely monitored for the six-month study period by study doctors.
People may be eligible to participate in this study if they:
- Are 6 to 12 years of age with a diagnosis or suspected diagnosis of an autism spectrum disorder
- Speak using at least two- to three-word phrases on a daily basis
- Have difficulty with motor coordination (in life skills such as dressing, hand writing, bike riding) or speech production
- Do not have history of premature birth, epilepsy, tuberous sclerosis or cardiovascular or hematological disease
This is a partial list of eligibility requirements. To inquire about eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.